GILD:NASDAQGilead Sciences, Inc. Analysis

Gilead Sciences (GILD) trades at $130.5, comfortably above its 200‑day SMA ($128.0) but below the 20‑day ($131.8) and 50‑day ($136.7) averages, indicating a short‑term pull‑back within a neutral trend. Technicals are mixed: RSI sits at 42 (neutral), MACD shows a bullish histogram (+0.02) and the stock sits near its $127.64 support with resistance at $137.5. The company delivered an 8% YoY revenue increase to $6.8 B in Q1 2026, driven by solid HIV product sales, while COVID‑19 treatment revenue has tapered off. Fundamentals remain strong – a 44% revenue growth rate, 79% gross margin, ROE of 43%, and a dividend yield of 2.53% with a modest 43% payout, suggesting cash‑flow sustainability. However, the DCF‑derived fair value of $89.9 is far below the market price, flagging the stock as overvalued despite analyst consensus (Buy) and a median target of $160, implying a 20% upside relative to current levels. The market sentiment is in “Extreme Greed” territory (FGI 89), which may be inflating price expectations.